HALOZYME THERAPEUTICS, INC.
Last 30 daysNo qualifying insider buying. Sales: $9.05M by 2 insiders.
Showing the first 6 of 20 trades on this page.
Director
Restricted Stock Units
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Option to Purchase Common Stock
Derivative security · not the ordinary share price.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
PRESIDENT AND CEO
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Restricted Stock UnitsGrant or award | Derivative units1,169Award · no purchase price | Non-cash award | Oct 1Filed Oct 2 · 1d later | SEC filing |
| Director | Option to Purchase Common StockGrant or award | Derivative units1,775Award · no purchase price | Non-cash award | Oct 1Filed Oct 2 · 1d later | SEC filing |
| Director | Common StockSale10b5-14 trades | 5,230avg $108.54 / share | $567.66K | Oct 1Filed Oct 2 · 1d later | 4 filings
|
| Director | Common StockSale10b5-14 trades | 18,996avg $107.74 / share | $2.05M | Sep 16Filed Sep 17 · 1d later | 4 filings
|
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Sep 9Filed Sep 11 · 2d later | SEC filing |
| PRESIDENT AND CEO | Common StockSale10b5-13 trades | 20,000avg $107.43 / share | $2.15M | Sep 9Filed Sep 11 · 2d later | 3 filings
|
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Sep 10Filed Sep 11 · 1d later | SEC filing |
| PRESIDENT AND CEO | Common StockSale10b5-12 trades | 20,000avg $107.17 / share | $2.14M | Sep 10Filed Sep 11 · 1d later | 2 filings
|
| PRESIDENT AND CEO | Common StockOption exercise or conversion10b5-1 | 20,000$18.41 / share | $368.2K | Sep 11Filed Sep 11 · 0d later | SEC filing |
| PRESIDENT AND CEO | Common StockSale10b5-12 trades | 20,000avg $107.24 / share | $2.14M | Sep 11Filed Sep 11 · 0d later | 2 filings
|
Showing the latest 20 of 122 trades. Show all 122 trades
Halozyme Therapeutics, Inc. - Common Stock (HALO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House member